A plain-language look at published BPC-157 blood vessel research, including the 2026 human artery tissue study, what ex vivo means, and what the studies do not show.
How standalone BPC-157 differs from the pre-mixed blends that contain it, what is in each vial, and why combining peptides is a research idea, not a proven bigger effect.
Side-by-side comparison of tirzepatide (GLP-1/GIP dual) and retatrutide (GLP-1/GIP/glucagon triple) — efficacy, mechanism, safety, and research selection criteria.


